No Data
Raygene (688217.SH): The company did not repurchase shares in October.
On November 4th, Raytheon Genomics (688217.SH) announced that in October 2024, the company did not repurchase any shares. As of October 31, 2024, the company has repurchased a total of 669,621 shares through the Shanghai Stock Exchange trading system by means of centralized bidding trading method, accounting for 1.20% of the company's total share capital of 55,855,896 shares. The highest price for repurchase transactions was 27.67 yuan per share, the lowest price was 22.37 yuan per share, and the total amount paid was RMB 17,021,747.99 (excluding stamp duty, trading commissions, and other transaction fees).
Rayon Genomics 2024 Third Quarter Report
Ruiai Gene (688217.SH): The net income for the first three quarters was 5.7273 million yuan, a decrease of 69.58% year-on-year.
On October 29, Genor Biopharma (688217.SH) announced that in the first three quarters of 2024, it achieved revenue of 0.19 billion yuan, a decrease of 4.62% year-on-year; net income attributable to shareholders of the listed company was 5.7273 million yuan, down 69.58% year-on-year; basic earnings per share was 0.10 yuan.
Shanghai Rightongene Biotechnology Co., Ltd. (SHSE:688217) Shares Fly 52% But Investors Aren't Buying For Growth
ReanGene (688217.SH) zhejiang Dahelth, a shareholder, reduced its holdings by 0.5576 million shares. The shareholding period has expired.
Raygene (688217.SH) announced that the company received a notice from zhejiang Dajian, a shareholder, on September 27, 2024...
Rayon Genomics 2024 Semi-Annual Report
No Data
